Increasing statin prescribing through a pharmacogenomics-guided initiative

IF 2.5 4区医学 Q3 PHARMACOLOGY & PHARMACY

Journal of the American Pharmacists Association Pub Date : 2025-08-08 DOI:10.1016/j.japh.2025.102898

Claire Rennie, Mary Roads, Bridger Bright, Sally Armstrong, Jennifer Meyer Reid

{"title":"Increasing statin prescribing through a pharmacogenomics-guided initiative","authors":"Claire Rennie, Mary Roads, Bridger Bright, Sally Armstrong, Jennifer Meyer Reid","doi":"10.1016/j.japh.2025.102898","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Despite clear benefits of statin therapy, utilization remains suboptimal. Concern for adverse effects are a top reason for declining or discontinuing a statin. Certain genetic variations can predispose a patient to statin intolerance.</div></div><div><h3>Objective</h3><div>To offer Veterans pharmacogenomics testing to help guide statin therapy decision-making and increase appropriate statin prescribing within a single Veterans Affairs Health Care System (VAHCS).</div></div><div><h3>Practive innovation & evaluation methods</h3><div>A team of pharmacists designed a quality improvement initiative that included personalized phone calls offering pharmacogenomics testing and/or statin initiation. Patients initiated on a statin were assessed for adherence and tolerability at least four weeks after initiation.</div></div><div><h3>Results</h3><div>A total of 107 patients were contacted for the statin initiative. About half (n = 50 [47%]) initiated a statin, and of those, 45 (90%) completed pharmacogenomics testing for a genomics-guided statin prescription. Most patients initiated on a statin (72%) reported adherence and tolerance at least 4 weeks after starting statin therapy.</div></div><div><h3>Conclusion</h3><div>Pharmacogenomics testing can potentially be used as a tool in the statin initiation process to facilitate a patient-centered discussion and increase shared clinical decision making.</div></div>","PeriodicalId":50015,"journal":{"name":"Journal of the American Pharmacists Association","volume":"65 6","pages":"Article 102898"},"PeriodicalIF":2.5000,"publicationDate":"2025-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the American Pharmacists Association","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1544319125005771","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Despite clear benefits of statin therapy, utilization remains suboptimal. Concern for adverse effects are a top reason for declining or discontinuing a statin. Certain genetic variations can predispose a patient to statin intolerance.

Objective

To offer Veterans pharmacogenomics testing to help guide statin therapy decision-making and increase appropriate statin prescribing within a single Veterans Affairs Health Care System (VAHCS).

Practive innovation & evaluation methods

A team of pharmacists designed a quality improvement initiative that included personalized phone calls offering pharmacogenomics testing and/or statin initiation. Patients initiated on a statin were assessed for adherence and tolerability at least four weeks after initiation.

Results

A total of 107 patients were contacted for the statin initiative. About half (n = 50 [47%]) initiated a statin, and of those, 45 (90%) completed pharmacogenomics testing for a genomics-guided statin prescription. Most patients initiated on a statin (72%) reported adherence and tolerance at least 4 weeks after starting statin therapy.

Conclusion

Pharmacogenomics testing can potentially be used as a tool in the statin initiation process to facilitate a patient-centered discussion and increase shared clinical decision making.

查看原文本刊更多论文

通过药物基因组学指导计划增加他汀类药物的处方。

背景：尽管他汀类药物治疗有明显的益处，但使用率仍然不够理想。对不良反应的担忧是减少或停用他汀类药物的首要原因。某些基因变异可使患者易患他汀类药物不耐受。目的：提供退伍军人药物基因组学检测，以帮助指导他汀类药物治疗决策，并在单一退伍军人事务卫生保健系统（VAHCS）内增加适当的他汀类药物处方。方法：一组药剂师设计了一项质量改进（QI）计划，其中包括提供药物基因组学测试和/或他汀类药物起始的个性化电话。开始服用他汀类药物的患者在开始服用后至少四周评估其依从性和耐受性。结果：共联系了107例他汀类药物患者。大约一半[n = 50(47%)]开始服用他汀类药物，其中45（90%）完成了基因组学指导的他汀类药物处方的药物基因组学测试。大多数开始使用他汀类药物的患者（72%）报告在开始他汀类药物治疗后至少4周的依从性和耐受性。结论：药物基因组学检测有可能作为他汀类药物起始治疗过程中的一种工具，促进以患者为中心的讨论，并增加共享的临床决策。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of the American Pharmacists Association 医学-药学

CiteScore

3.30

自引率

14.30%

发文量

336

审稿时长

46 days

期刊介绍： The Journal of the American Pharmacists Association is the official peer-reviewed journal of the American Pharmacists Association (APhA), providing information on pharmaceutical care, drug therapy, diseases and other health issues, trends in pharmacy practice and therapeutics, informed opinion, and original research. JAPhA publishes original research, reviews, experiences, and opinion articles that link science to contemporary pharmacy practice to improve patient care.